2
Clinical Trials associated with MSP3-CRM-Vac4All/Alhydrogel / Unknown statusPhase 1/2 A Phase 1b/2b Double Blind, Randomized, Controlled Study of the Safety, Immunogenicity, and Efficacy of Malaria Vaccine Candidate MSP3-CRM-Vac4All/ Alhydrogel® in Young Children in Mali
Two-arm, randomized, double-blinded and controlled clinical trial to first assess the safety and tolerability of the vaccine in a Phase 1b trial and proceed to assess its efficacy against clinical malaria in young children living in highly seasonal malaria areas of Mali
/ Active, not recruitingPhase 1 Phase 1 Randomized, Dose-finding Study to Evaluate the Safety, Tolerability and Immunogenicity of a Novel Malaria Vaccine, MSP3-CRM-Vac4All/ Alhydrogel®, in Healthy Adults
First-in-Human, Randomised, Dose-Finding Single Center Study to evaluate three dose levels of a novel malaria vaccine, MSP3-CRM-Vac4All/ Alhydrogel® : 3 µg, 10 µg and 30 µg
100 Clinical Results associated with MSP3-CRM-Vac4All/Alhydrogel
100 Translational Medicine associated with MSP3-CRM-Vac4All/Alhydrogel
100 Patents (Medical) associated with MSP3-CRM-Vac4All/Alhydrogel
100 Deals associated with MSP3-CRM-Vac4All/Alhydrogel